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Longer treatment time (TT) and slower ultrafiltration rate
(UFR) are considered advantageous for hemodialysis (HD)
patients. The study included 22 000 HD patients from seven
countries in the Dialysis Outcomes and Practice Patterns
Study (DOPPS). Logistic regression was used to study
predictors of TT4240 min and UFR410 ml/h/kg bodyweight.
Cox regression was used for survival analyses. Statistical
adjustments were made for patient demographics,
comorbidities, dose of dialysis (Kt/V), and body size. Europe
and Japan had significantly longer (Po0.0001) average TT
than the US (232 and 244 min vs 211 in DOPPS I; 235 and
240 min vs 221 in DOPPS II). Kt/V increased concomitantly
with TT in all three regions with the largest absolute
difference observed in Japan. TT4240 min was
independently associated with significantly lower relative risk
(RR) of mortality (RR¼ 0.81; P¼ 0.0005). Every 30 min longer
on HD was associated with a 7% lower RR of mortality
(RR¼ 0.93; Po0.0001). The RR reduction with longer TT was
greatest in Japan. A synergistic interaction occurred between
Kt/V and TT (P¼ 0.007) toward mortality reduction.
UFR410 ml/h/kg was associated with higher odds of
intradialytic hypotension (odds ratio¼ 1.30; P¼ 0.045) and a
higher risk of mortality (RR¼ 1.09; P¼ 0.02). Longer TT and
higher Kt/V were independently as well as synergistically
associated with lower mortality. Rapid UFR during HD was
also associated with higher mortality risk. These results
warrant a randomized clinical trial of longer dialysis sessions
in thrice-weekly HD.
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Hemodialysis (HD) patients continue to experience high
mortality rates.1 Several studies have suggested that longer
duration of HD sessions is associated with a survival
advantage.2–6 A recent US study, however, failed to confirm
this relationship.7 Potentially, long, slow dialysis sessions may
result in improved middle molecular clearance and better
blood pressure and volume control, particularly if high-flux
dialysis membranes are used.8,9 The National Cooperative
Dialysis Study suggested a survival advantage with longer
treatment times.10,11 This clinically important trend failed to
capture the attention of the nephrology community, perhaps
because of its P-value of 0.06. The recently completed
Hemodialysis (HEMO) Study focused on dialysis dose as
measured by urea kinetics (Kt/V) and membrane flux,12
rather than the length of dialysis treatments.
Excessive interdialytic weight gain has been shown to be
an independent predictor of mortality in a number of obser-
vational studies.13,14 Although higher interdialytic weight
gain is associated with better nutritional indices, it predis-
poses to volume overload, which causes abnormal ventricular
remodeling resulting in heart failure.15–17 Those with
excessive interdialytic weight gain tend to receive a higher
ultrafiltration rate (UFR) (i.e., rate of volume removal during
HD), potentially resulting in increased frequency of intra-
dialytic hypotension (IDH). IDH in turn could result in
altered sensorium, myocardial ischemia and infarction,
blindness, and even stroke.18,19 Although it is not entirely
clear that recurrent IDH is associated with higher mortality,20
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it is plausible that a lower UFR would decrease its incidence
and severity, thereby reducing the potential for recurrent
hypotensive injury to vital organs.
This study examines the relationship between treatment
time (TT) and UFR with patient outcomes in the Dialysis
Outcomes and Practice Patterns Study (DOPPS), an interna-
tional, prospective cohort study of HD patients and facilities.
RESULTS
Distribution of TT and UFR
Average facility TT was normally distributed across the
DOPPS regions with the mean and median at 228 and
229 min, respectively (Figure 1a). Approximately half the
patients were receiving a TT of 211–240 min (3.5–4 h), where-
as 27.1% had TT4240 min and 22.2% had TTo211 min.
Table 1 shows the average (7s.d.) TT in DOPPS I and II
in each region at the patient level. In both DOPPS I and
DOPPS II, mean TTs for Japan and Europe were significantly
longer than those in the US after accounting for facility
clustering effects. TT in the US increased significantly between
DOPPS I and DOPPS II – from 211 to 221 min – whereas there
was no significant change in mean TT in the other DOPPS
regions.
Overall, the mean UFR was 8.9 ml/h/kg, whereas the
median value was 9.0 ml/h/kg (Figure 1b). In DOPPS I, the
average UFR was significantly lower in Japan and Europe
than in the US (Table 1). In Japan, this rate increased
significantly (Po0.05), from 8.2 in DOPPS I to 9.973.6 in
DOPPS II.
Relationship of TT and Kt/V
The mean (7s.d.) Kt/V values in Japan, Europe, and the US
were 1.3470.26, 1.3670.25, and 1.4170.26, respectively.
The corresponding 10–90th percentile ranges were 1.03–1.67,
1.09–1.70, and 1.13–1.70, respectively. The mean Kt/V values
at four different TT values (180, 210, 240, and 270 min) were
examined by region. In Japan, the Kt/V values were 1.167
0.22, 1.2370.23, 1.3370.23, and 1.4370.26, respectively,
reflecting increasing Kt/V by increasing TT (Po0.0001). In
Europe, the corresponding values were 1.2970.25, 1.367
0.26, 1.3870.26, and 1.3670.21 (Po0.0001), respectively. In
the US, they were 1.3770.26, 1.4370.27, 1.4370.27, and
1.3870.23 (Po0.0001), respectively. The unadjusted corre-
lations of TT and Kt/V were therefore examined in each
DOPPS region to assess the feasibility of testing the inde-
pendent effects of each of the two variables in the Cox
models. In Japan, the r2 for the correlation was 0.14 (P¼
0.0001); in Europe it was 0.03 (P¼ 0.0001); and in the US
it was 0.01 (P¼ 0.0001). For every 30 min longer TT, the
Kt/V value was higher by 0.08 in Japan (Po0.0001), 0.03
(Po0.0001) in Europe, and 0.02 in the US (Po0.0001).
Factors associated with longer TT and higher UFR
Descriptive characteristics and statistically significant ad-
justed odds ratios from logistic regression models for two
categories of TT (4240 min and p240) and UFR (410 and
p10 ml/h/kg) are shown in Table 2a and b.
Mortality risk and TT
Using TT4240 min as the referent category, the relative
risk (RR) of mortality for TTo211 min was 1.34 (Po0.0001)
and the RR of mortality for TT of 211–240 min was 1.19
(P¼ 0.01) (Figure 2). Table 3 shows the unadjusted and
adjusted RR of all-cause and cardiopulmonary mortality
by TT4240 min (vs p240 min). After adjustment, TT
longer than 240 min (vs p240 min) was associated with a
19% lower RR of all-cause mortality (P¼ 0.0005) and 16%
lower RR of cardiopulmonary mortality (P¼ 0.03). The
differences between unadjusted and adjusted results are
partly explained by the substantially younger age of patients
treated with longer TT (Table 2a). Considering TT modeled
































Figure 1 | (a) Distribution of facility mean TT, by region and phase
of DOPPS (n=546 facilities). (b) Distribution of facility mean UFR, by
region and phase of DOPPS (n¼ 531 facilities).
Table 1 | Average (7s.d.) treatment time (TT) and
ultrafiltration rate (UFR) by region and phase of study for
a prevalent cross-section of patientsa
DOPPS I DOPPS II
Region n Mean n Mean
TT (min)
Europe 2590 232b741 2856 235b738
Japan 2169 244b732 1805 240b733
US 3856 211732 2260 221c733
UFR (ml/h/kg)
Europe 2590 8.3b73.6 2856 8.4b73.5
Japan 2169 8.2b73.5 1805 9.9c73.6
US 3856 9.273.9 2260 9.873.7
aAccounts for facility clustering.
bPo0.05 vs US within phase.
cPo0.05 comparing DOPPS II to DOPPS I within each country.
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the RR of mortality was 7% lower (RR¼ 0.93; Po0.0001).
Figure 3 displays the effect of TT in the three DOPPS regions.
For every 30 min longer, the RR of mortality was 4% lower in
the US (RR¼ 0.96; P¼ 0.04), 6% lower in Europe (RR was
0.94; P¼ 0.01), and 16% lower in Japan (RR¼ 0.84;
Po0.0001).
Mortality risk and Kt/V
A significant relationship between Kt/V and RR of mortality
was observed, independent of TT. For every 0.1 higher Kt/V,
the RR of mortality was 2% lower, with (P¼ 0.012) and
without (P¼ 0.001) adjustment for TT.
Table 2 | (a) Statistically significant predictors of having a treatment time 4240 min (b) Statistically significant predictors
of having UFR410 ml/h/kg
(a) Statistically significant predictors of having a treatment time 4240 min
Mean or %
Characteristic (reference for OR) TT4240 min (n=1980) TTp240 min (n=14 353) OR (TT4240 vs p240 min)a
Age (per 10 years) 56.4 62.0 0.83z
Male (vs female) 70.1 56.1 1.59z
Black (vs non-black) 11.4 15 1.54z
Time on dialysis (per year) 7.2 3.56 1.07z
Prior transplant (yes vs no) 7.8 5.4 0.58z
Employed (yes vs no) 27.0 14.9 1.15
Disabled (yes vs no) 16.2 14.4 1.19z
Comorbidities (yes vs no)
Cardiac disease other than CAD or CHF 33.7 32.1 1.19z
Diabetes 29.2 36.5 1.14w
Intradialytic weight loss 45.7% (yes vs no) 12.2 5.6 2.58z
Height (per 1 cm) 168 165 1.02z
Weight (per kg) 71.5 66.4 1.04z
Kt/V (per 0.1) 1.43 1.33 1.20z
Residual renal function (yes vs no) 15.3 23.8 0.62z
UFR410 ml/h/kg 27.1 36.3 0.62z
(b) Statistically significant predictors of having UFR410 ml/h/kg
Mean or %
Characteristic UFR410 (n=5759) UFRp10 (n=10 599) OR (UFR410 vs p10 ml/h/kg)b
Age (per 10 years) 59.9 62.0 0.91z
Time on dialysis (per year) 4.8 3.5 1.02z
Comorbidities (yes vs no)
CHF 32.1 29.3 1.19z
Cardiac disease (other than CAD or CHF) 34.3 31.2 1.12z
Smoker 22.5 18.9 1.14w
Hypertension 77.2 76.5 1.12w
Diabetes 35.7 35.6 1.19z
Kt/V (per 0.1) 1.4 1.31 1.06z
Weight (per kg) 63.4 69.1 0.98z
Intradialytic weight loss 45.7% (yes vs no) 18 0.2 79.1z
Residual renal function (yes vs no) 17 25.9 0.68z
TT4240 min 9.3 13.6 0.51z
Catheter as vascular access 14.9 22.0 0.64z
CAD, coronary artery disease; CHF, congestive heart failure; TT, treatment time; UFR, ultrafiltration rate.
w0.01oPo0.05. zPo0.01.
aOR adjusted for factors listed above and for ethnicity, 12 summary comorbid conditions, living status, marital status, depression, prior kidney transplant, catheter use as
vascular access, geographical region, and DOPPS I vs DOPPS II. Accounts for facility clustering.
bOR adjusted for factors listed above and for sex, race, ethnicity, nine summary comorbid conditions, living status, marital status, depression, prior kidney transplant, height,

























Figure 2 | RR of all-cause mortality, by TT category.
The incremental RR of mortality with decreasing TT categories in
all DOPPS regions combined. The referent category is TT44 h
(240 min).
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Interaction between TT and Kt/V
A significant interaction between Kt/V and TT was found in
the multivariable survival models (P¼ 0.007; Figure 4). At
any level of Kt/V, a longer TT was associated with lower RR of
mortality. Furthermore, at higher levels of Kt/V, a longer TT
was even more beneficial than the same TT for a lower level
of Kt/V, suggesting a synergistic relationship between TT and
Kt/V with respect to mortality risk reduction. This interac-
tion occurred in the same direction in all regions and was not
significantly different by region.
UFR, mortality risk, and intradialytic hypotension
UFR410 ml/h/kg was associated with an elevated risk of
mortality (RR¼ 1.09; P¼ 0.02, with TT in the Cox model)
(Table 3). However, there was no significant trend in
mortality risk with lower categories of UFR. UFR410 ml/
h/kg was significantly associated with 30% higher odds of
IDH (P¼ 0.045). TT, however, was not associated with
increased risk of IDH, with UFR in the model.
DISCUSSION
The main findings from this study are that, in the setting
of conventional thrice-weekly HD: (1) longer HD session
duration is independently associated with lower mortality,
(2) a synergistic mortality-reducing interaction exists bet-
ween Kt/V and TT (i.e., more pronounced RR reduction at
higher Kt/V combined with longer TT), and (3) a faster rate
of fluid removal at dialysis as measured by UFR410 ml/h/kg
body weight is associated with both higher risk of morta-
lity and increased odds of intradialytic hypotension. We
also confirm prior reports from observational studies21 that
higher Kt/V is a significant and independent predictor of
lower mortality, both with and without adjustment for TT.
Many investigators have stressed the importance of
prolonging TT in HD.2,22–27 Prior observational studies have
pointed to the possible significance of dialysis session length.
Held et al5 investigated the relationship of 3-year mortality
and TT in a random sample of 600 HD patients from 36
dialysis units using low flux dialyzers only and found that TT
o3.5 h was associated with significantly higher mortality.
However, that study was conducted at a time (1984–1985)
when urea kinetic modeling was not widely practiced in the
US. Although it adjusted for a variety of patient, provider,
and geographic covariates, it did not adjust for Kt/V and the
authors could not rule out reduced delivered Kt/V in the
group dialyzing for shorter durations. Recent data from the
Australia and New Zealand Dialysis and Transplant Registry
indicate that dialysis duration of 44.5 h may be associated
with a lower RR of mortality, and durationo3.5 h associated
with a higher mortality risk.28 Similar results have been
reported from the Japanese HD registry.6 A recent large US
study was unable to demonstrate the effect of TT indepen-
dent of measures of body size and small solute clearance.7
The authors reasoned that the narrow range of TT in their
cohort, reflecting the practice norm in the US, might help to
explain why the independent effect of TT did not emerge in
their analysis. The NIH-sponsored National Cooperative
Dialysis Study that investigated urea clearance and dialysis
duration in a 2 2 factorial design found that patients
with high blood urea nitrogen and short dialysis time
were hospitalized more often than the group with high
blood urea nitrogen but longer dialysis.10,11 Although this
result was statistically nonsignificant (P¼ 0.06), and may
have been the result of higher delivered Kt/V in the longer
Table 3 | Associations between ultrafiltration rate (UFR) and
treatment time (TT) and mortality
UFR410 ml/h/kg TT4240 min
Outcome RR P-value RR P-value
All-cause mortality
Unadjusted 1.01 0.75 0.68 o0.0001
Adjusteda 1.09 0.02 0.81 0.0005
Cardiopulmonary mortality
Unadjusted 1.00 0.97 0.73 o0.0001
Adjusteda 1.04 0.41 0.84 0.03
aBased on Cox regression, adjusted for: age, sex, race, ethnicity, time on dialysis, 14
summary comorbid conditions, living status, height, weight, Kt/V, blood flow,
residual renal function, and catheter use as vascular access, TT (in UFR model), and
UFR (in TT model). Stratified by geographical region and phase of study. Accounts
for facility clustering.


















Figure 3 | RR of mortality and TT, by region. The RR of mortality (on
a log scale) and TT by region (overall RR¼ 0.93 per 30 min
(Po0.0001). Although the association was statistically significant in
each region, it was strongest in Japan (RR¼ 0.84 per 30 min;
Po0.0001), followed by Europe (RR¼ 0.94 per 30 min; P¼ 0.01) and
the United States (RR¼ 0.96 per 30 min; P¼ 0.04). The thick solid lines
represent the highest concentration of patients in each distribution
(50% or more); the thin solid lines represent 10–25% of patients; the
dotted lines represent the lowest concentration of patients (o10%).
















Figure 4 | Interaction between Kt/V and TT. The incremental RR of
mortality (on a log scale) by TT (x-axis) for patients in three different
categories of Kt/V (interaction P¼ 0.007), illustrating that the effect of
TT is greater at higher Kt/V.
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dialysis arm, its potential clinical importance was not
emphasized. The rather small sample (n¼ 151) and the
premature stopping of the National Cooperative Dialysis
Study may have led to the study being underpowered to
demonstrate a clinically significant difference between the
long and short treatment arms. A small, randomized trial
of 4 vs 5 h of dialysis demonstrated better tolerability of
the longer dialysis sessions but did not study long-term
outcomes.24 The experience from Tassin, France,2 and the
centers performing slow nocturnal dialysis25 have repeatedly
emphasized the importance of HD session length, reporting
consistently excellent results, especially with respect to blood
pressure control, reduced erythropoietin requirements, fluid
management, reduced frequency of IDH, and improved
quality of life. However, these times are substantially longer
than those reported in our study and therefore not strictly
comparable.
Longer dialysis duration may be beneficial in several ways:
improved tolerability of the treatment (primarily the result
of slower UFR), greater removal of uremic toxins, parti-
cularly middle molecules, better control of blood pressure,
and better volume management. These mechanisms may in
turn reduce cardiovascular morbidity and mortality. Longer
TT is utilized in clinical practice as one of the methods to
increase delivered Kt/V. This was most apparent in Japan
where Kt/V was 1.1670.22 when TT was 180 min (3 h) and
1.4370.26 when TT was 270 min (4.5 h). Although there
were statistically significant correlations between TT and
Kt/V (strongest in Japan, but also statistically significant in
Europe and the US, owing to the large sample sizes), they
were not of sufficient magnitude (r2¼ 0.14 in Japan, and
much lower in Europe and the US) to preclude examining
the effect of TT on mortality independent of Kt/V. If TT
and Kt/V had been highly correlated, we would not have
been able to separate their independent effects in a model
that adjusted for both variables. Instead, we have found both
variables to be significant in the same model; furthermore,
their interaction was significant. Although this does not
negate the fact that longer TT increases Kt/V and could in
part reduce mortality by that mechanism, it points even more
importantly to the effect of TT over and above that obtained
by a higher delivered Kt/V alone. Not only does it highlight
the significance of TT independent of Kt/V, but it also
suggests that increasing TT could further enhance the
beneficial effect of a given Kt/V. Our results with respect to
the association of Kt/V and survival are consistent with the
direction of the effect seen in the intention to treat analysis
of the HEMO Study,12 which showed a nonsignificant risk
reduction with higher dose of dialysis. Our results are
consistent with results from other large observational studies
(reviewed in Saran et al.21).
In our study, the association of longer TTs and lower
mortality was strongest in Japan, followed by Europe and the
US (Figure 3). Although the explanation for this somewhat
differential gradient in the relationship by region is not
entirely clear, it may be due in part to the fact that in
Japan, Kt/V targets are more often achieved by prolonging
TT, whereas in Europe or the US, reliance on blood flow
rates and dialyzer size to achieve Kt/V targets may be more
common. These pertinent issues should be examined in
future analyses. Other possible explanations include: (a) the
US having the fewest patients treated in dialysis sessions
44 h (8.2%); (b) the effect of longer dialysis on mortality
being confounded by its selective prescription in younger
men with larger body size, beyond what is captured by
adjustment for height, weight, and age; and (c) non-adhe-
rence with HD as manifested by shortening and skipping
treatments (both statistically significant predictors of
mortality in the Cox models) being more prevalent in
the US13 than in Europe and Japan, which may result in
a larger gap between prescribed and delivered dialysis
dose in the US, thereby confounding the relationship
between TT and mortality. Although the source of regional
differences is not completely clear, the Cox model that
combines data from all DOPPS stratified by region essen-
tially pools the stratum-specific estimates. The fact that a
benefit of longer TT was observed in each of three widely
dispersed geographic regions, albeit with some variation in
magnitude, lends credence to the demonstrated significant
relationship between TT and mortality in all regions
combined.
It is a common clinical observation that rapid ultrafiltra-
tion often results in IDH. A considerable body of literature
deals with management of IDH, with significant advances in
dialysis technology pertaining to sodium as well as online
hematocrit modeling.26,27,29–31 However, the fundamental
relationship between UFR and patient outcomes has not
received the attention it deserves in the HD literature.
Few studies have examined the direct association of UFR
on long-term outcomes in HD patients. The Netherlands
Cooperative Study on the Adequacy of Dialysis recently
reported the association between excessive ultrafiltration
(measured as total weekly ultrafiltration) and mortality,
independent of delivered Kt/Vurea.
32 High interdialytic weight
gain, volume expansion, the economic barriers to long-
duration HD, and the inherent ‘unphysiology’ of thrice-
weekly HD all predispose patients to the necessity for higher
UFR with increased frequency of IDH. The finding of
significant association of UFR with both mortality and IDH
provides one possible mechanism for the protective effect of
longer TT, which was significantly associated with lower odds
of high UFR in the logistic models (Table 2a and b).
The strengths of the present analysis are the large number
of randomly selected HD patients in an international,
representative sample of dialysis facilities and the ability
to adjust for a variety of case-mix factors, including measures
of body size and dialysis dose as measured by Kt/V, and to
take into account the presence or absence of residual renal
function. Stratification by geography and accounting for
facility clustering are also important elements of these
analyses demonstrating the differential effects of TT on
mortality by region.
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We recognize certain limitations of this work. It is an
observational study that can only infer association and not
causality. Although we have adjusted for a variety of case-
mix-related factors, the possibility of residual confounding
remains, especially considering the regional variation in
results. The precise mechanisms for the apparent greater
benefit of longer TT in Japan vs Europe and the US are not
clarified by this study and warrant further investigation. TT
and UFR are measured at baseline and could potentially
change over time. This report does not include time-
dependent analyses due to non-availability of serial TT data
in the DOPPS. There are no serial measurements of dry
weight in the DOPPS, and we cannot accurately determine
whether longer TT was associated with better achievement of
dry weight. Last but not least, there were not many patients
with dialysis sessions longer than five hours.
SUMMARY AND CONCLUSIONS
This study demonstrates that the duration of HD session
is independently associated with a lower mortality risk
after extensive adjustment for case mix, dialysis dose (Kt/V),
body size measures, and indicators of non-adherence.
The observed synergistic interaction between Kt/V and TT
toward mortality risk reduction implies that delivering a
high Kt/V over longer TT may be of greater value than
delivering the same Kt/V over shorter TT (with implications
for practice modification). Furthermore, this study finds that
UFR410 ml/h/kg body weight is independently associated
with higher risk of both intradialytic hypotension and morta-
lity. However, since this is an observational study and
causality is not proven, the issues of TT and UFR merit
further examination by a prospective randomized clinical
trial in the setting of thrice-weekly HD, as this is likely to
remain the paradigm for the majority of HD patients for the
foreseeable future. Until results from such a trial are available,
we believe this large international prospective cohort study
provides support for the view that longer HD sessions could
improve outcomes for HD patients receiving thrice-weekly HD.
MATERIALS AND METHODS
Data source
The patient sample was drawn from the combined database for
DOPPS I (1997–2002) and DOPPS II (2002–2004), but included
information about HD patients in only those countries that
participated in both phases (France, Germany, Italy, Japan, Spain,
the UK, and the US). A nationally representative sample of dialysis
facilities was enrolled in each country, and a random sample of HD
patients was selected from each participating facility. Details of study
design, facility sampling, patient sampling, and data collection for
DOPPS have been published previously.33 The current study reflects
data obtained from the United States (DOPPS I: 145 facilities,
n¼ 9500; DOPPS II: 79 facilities, n¼ 3500), Euro-DOPPS countries
(DOPPS I: 101 facilities, n¼ 4500; DOPPS II: 101 facilities,
n¼ 4000), and Japan (DOPPS I: 65 facilities, n¼ 2700; DOPPS II:
60 facilities, n¼ 2800).
An average of 30 adult chronic HD patients (18 years old
or older) participated from each facility. Data collection began in
the US in June 1996, in Europe in May 1998, and in Japan in
February 1999. Patients were followed until January 2002 in the
US, November 2000 in Europe, and October 2001 in Japan. DOPPS
II data collection began in 2002 and concluded in 2004 in all seven
countries. A study coordinator at each dialysis center collected data
using standardized chart abstraction. For this analysis, only preva-
lent patients from each facility were included. Follow-up informa-
tion was obtained approximately every 4 months and included dates,
diagnoses, and procedures associated with each hospitalization.
Definitions used in this study
Treatment time. The duration of dialysis session used in this
analysis came from the dialysis prescription information.
Dialysis dose (Kt/V). The dialysis dose was expressed as
single pool Kt/V that was calculated using the second-generation
Daugirdas formula.34
Ultrafiltration rate. The rate of volume removal at dialysis,
expressed in ml/h/kg bodyweight, was based on the weight change
per TT, using the post-dialysis weight in the denominator.
Intradialytic hypotension. Any systolic blood pressure drop of
X30 mmHg combined with a post-dialysis systolic pressure of
p100 mmHg was considered evidence of IDH.
Statistical analysis
Average UFRs and TTs were compared across geographical regions
using the initial prevalent cross-sections, which included 8615
patients from DOPPS I and 6921 patients from DOPPS II. All other
analyses used the complete sample of more than 22 000 patients.
Logistic regression was used to investigate the odds of TT4240 min
vs TTp240 min (240 min is usually considered the clinical threshold
for longer dialysis) and of UFR410 ml/h/kg vs UFRp10 ml/h/kg.
These models investigated patient characteristics, including age, sex,
race, 15 summary comorbid conditions, time since initiation of
dialysis (i.e., vintage), post-dialysis weight, height, Kt/V, intradialytic
weight loss, living status (e.g., alone, nursing home), marital status,
prior kidney transplant, geographical region, TT (in UFR model),
and UFR (in TT model). The intermediate outcome of intra-
dialytic hypotension was examined using logistic regression, and the
odds ratio for patients with UFR410 ml/h/kg vs UFRp10 ml/h/kg
was estimated. This model was also adjusted for all variables listed
above.
Patient risk of mortality was assessed using Cox proportional
hazards regression, stratified by the three geographical regions (US,
Europe, and Japan) and by the two phases of DOPPS. Both all-cause
mortality and cardiopulmonary mortality (including deaths attrib-
uted to myocardial infarction, pericarditis, atherosclerotic heart
disease, cardiac arrest, valvular heart disease, pulmonary embolism,
cardiomyopathy, cardiac arrhythmia, pulmonary edema, hyper-
kalemia, and congestive heart failure) were investigated. Models
included significant predictors of mortality: age, sex, race/ethnicity,
time on dialysis, height, weight, Kt/V, employment status, TT,
residual renal function, measures of non-adherence (shortening of
HD by at least 10 min/month and skipping at least one HD session/
month as defined in our previous publication13), and 14 summary
comorbid conditions. A separate Cox model was run to examine
TT trends by region using interaction terms. Interactions were used
to allow different associations between mortality and the following
adjustment variables by region: age, male, history of transplant,
catheter as access type, and weight (in Japan only). These models
included both TT and UFR as predictors of mortality. The
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association between UFR and mortality was consistent by region.
The linear assumption for TT was verified using model fit statistics
and plots of Martingale residuals from the Cox models vs TT. An
interaction between Kt/V and TT was also tested. All models
accounted for clustering at the facility level. For the logistic
regression models, facility clustering was accommodated using
generalized estimating equations, assuming an exchangeable work-
ing covariance structure.35 For the Cox regression models, the
robust sandwich estimator, assuming an independence working
covariance structure, was used to account for clustering at the
facility level.36 All statistical analyses were carried out using SAS
software (version 9.1).
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